Business leverages dual-market method and technology-driven standardization to reinforce its management in China’s TCM sector and go into global markets.
Sichuan Neautus Traditional Chinese Medicine Co., Ltd. has actually sent a listing application to the Hong Kong Stock Exchange. The IPO is planned to raise capital to support the business’s growth both locally and globally amidst quick modernization of China’s conventional Chinese medication (TCM) market.
Established in 2021, Chengdu, China, Neautus has actually become a leading gamer in the organic preparation pieces market, with yearly income surpassing RMB 1.2 billion.
Double Growth Engines
Neautus runs a “dual-engine” development design, stabilizing institutional sales and customer need.
The business provides more than 1,000 significant healthcare facilities in China and is continuing to grow. And through its B2B platform, “Jinfang Caotang,” which is an online platform targeted at satisfying the needs of around 90,000 TCM centers in China, the business has actually seen substantial success. Considering that the launch of “Jinfang Caotang,” the platform has actually drawn in over 5,200 signed up TCM centers within a year, signifying high development.
In the customer market, Neautus concentrates on ready-to-consume organic supplements targeted at a varied market of Traditional Chinese Medicine (TCM) users in China. Furthermore, the business has actually broadened its reach into abroad markets, consisting of Hong Kong, Taiwan, Vietnam, and Malaysia.
Technology-Driven Standardization
Neautus is the very first business worldwide to use DNA barcoding innovation to recognize natural products, a basic acknowledged by both the Chinese and British Pharmacopoeias. This accomplishment made the business the National Science and Technology Progress Award (Second Class). Recently, Neautus has actually likewise acquired a series of top-level accreditations– from “Chengdu Digital Workshop” to Sichuan Province’s “Advanced Smart Factory”– highlighting its development towards Intelligentization 2.0.
Market Tailwinds and Global Expansion
Supported by nationwide policies promoting standardization, Frost & & Sullivan tasks China’s TCM market will surpass RMB 599.3 billion by 2030. IPO profits will money abroad capability, worldwide accreditations, cross-border e-commerce, local acquisitions, and entry into European and U.S. markets. The business is likewise intending on establishing AI-assisted diagnostic tools through its “Jinfang Cloud” platform.
IPO Outlook
The IPO highlights Sichuan Neautus’s function in changing the TCM market from conventional production to value-driven health care development, while additional reinforcing its position as a market leader and advancing the sector towards greater requirements and quality.
About Sichuan Neautus Traditional Chinese Medicine Co., Ltd.
Sichuan Neautus Traditional Chinese Medicine Co., Ltd. concentrates on top quality natural preparation pieces and health supplements, integrating innovation, traceability, and research study to serve domestic and worldwide markets.
Subject: Press release summary
Sectors: Healthcare & & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights scheduled. A department of Asia Corporate News Network.
